In recent years, immunotherapy based on monoclonal antibodies targeting immune checkpoint programmed cell death-1 (PD-1) and programmed cell death-1 ligand (PD-L1) has achieved remarkable clinical success and shown unprecedented durable responses for NSCLC patients without an actionable driver mutation (5–8). The gene discussed is CD274; the disease is non-small cell lung carcinoma.